Reading Time: 3 minutes Promising results from a Phase II clinical trial for a drug called NP001 have been announced by the biopharmaceutical company Neuraltus. The trial, conducted in America, suggested that NP001 is safe, well tolerated and could be beneficial for MND. Following these encouraging results, Neuraltus plan to begin a larger, Phase III trial of NP001 in the second half…
Reading Time: 9 minutes I’m sure many of you who follow our blog have also been following the discussion on our forum about the Neuraltus trial for a drug called NP001. First of all, thanks to ‘Matt J’ for initially raising this issue on our forum. It highlights the power of the forums in facilitating information spread and getting new news…
Reading Time: 3 minutes This blog is part of the ‘Highlights from Glasgow’ collection of articles, where you can read about the content of some of the talks and posters presented at the 29th International Symposium on ALS/MND. In the Clinical trials and trial design (4B) session we heard from two speakers looking at ways to improve current design…
Reading Time: 3 minutes The MND Association’s Director of Research, Brian Dickie explains more about ‘GM6’, also known as ‘GM604’, a drug in development by an American pharmaceutical company Genervon. The Association funds a wide range of research that leads to new understanding and treatments, which may one day, bring us closer to a cure for MND. We are hopeful…
Reading Time: 4 minutes At this time of year, it’s always good to look back on the previous year to see just how far we’ve really come. We’re pleased to say that 2012 was full of progress being made in the world of MND research and we hope that the speed and number of exciting findings being announced continues…
Reading Time: 2 minutes Each year we proudly organise the International Symposium on ALS/MND, and this year was a record breaker! The symposium was held in Chicago where over 900 clinicians, scientists and healthcare professionals attended the three-day event. With 86 international speakers and over 300 posters we managed to write about it all in just over 5,000 words in our daily articles on this blog. Here’s a brief guide…
Reading Time: 3 minutes A very much ‘must report on’ session of the 23rd International Symposium on ALS/MND was the clinical trials and trial design session. There are many reasons that make this an interesting session – perhaps the most eagerly anticipated were the presentations on the NP001 study and the results of the stem cell safety trial: NP001…
Reading Time: 2 minutes We organise the International Symposium on ALS/MND every year, and it is regarded as the premier medical conference on MND and a highlight of the research calendar. In 2011, the symposium was held in Sydney Australia where 650 researchers, clinicians and healthcare professionals from 33 countries met to discuss recent advances in MND research and…
Reading Time: 3 minutes “After a time where patients and sponsors of trials alike had become disheartened about the lack of positive clinical trials, it is exciting to see so many positives, including the recently approved Neudexta, and the dexpramipexole study”, commented Professor Robert Miller from the Forbes Norris ALS/MDA centre in San Francisco opening the discussions on clinical…
